This is a false notion. It is like saying, as was suggested last night that because an airline leases it’s planes from often an entity created specifically to buy and lease the planes to it that somehow that is a bad thing for the airline shareholders. No it is not. It is just a different capital structure, and in most instances it is more flexible and more advantageous where things do not turn out as expected. It’s lower risk.
It also requires far less dilution at a time when dilution is costly.
The notion that they should be scaled up for production before they can even present TLD, let alone make an application with numerous employees, is silly.
And lastly, NWBO owns everything but the employees and that is easily remedied if they want to go that route later.
This notion that a different capital structure is BAD is just more of the same silliness that has been a part of telling funky stories about this company.
They should be contract manufacturing anyway, but one key way they are going to protect their IP, is obviously also via trade secret. They are still improving manufacturing and inventing, and a contract manufacturer that is working for every other cell therapy company will likely learn from this process and take anything that is not nailed down, and the key to their IP protection is also about process and trade secrets. So again, I have no problem with their approach because I think it is intended to protect shareholders maximally, not the opposite of that. And it’s why it has gone to court once and ended up settled, and then critics had the SEC look into it, and while they have tweaked the process of the board ensuring things are negotiated arms length, and that is something organizations and law firms do all the time, I know from real life, nothing not kosher has been found at anytime.
It’s just noise at this point. You may not like it for whatever reason, but there is nothing necessarily wrong with de facto.
